DNTH (Dianthus Therapeutics) Beneish M-Score: 0.11 (As of Jul. 05, 2026) — 98% Below Median


DNTH Dianthus Therapeutics Inc DNTH
22 GF Score
Price $94.34
GF Value $2.91
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Dianthus Therapeutics Beneish M-Score?

Dianthus Therapeutics DNTH +4.58% 22 Beneish M-Score is 0.11 as of Jul. 05, 2026, which is 98% below its 10-year median of 6.35. GuruFocus rates DNTH with a GF Score™ of 22/100 and a GF Value™ of $2.91 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 825 Biotechnology companies, Dianthus Therapeutics ranks worse than 84.12% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 0.11 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Dianthus Therapeutics's Beneish M-Score or its related term are showing as below:

DNTH' s Beneish M-Score Range Over the Past 10 Years
Min: -4.75   Med: 6.35   Max: 124.08
Current: 0.11

During the past 5 years, the highest Beneish M-Score of Dianthus Therapeutics was 124.08. The lowest was -4.75. And the median was 6.35.


Dianthus Therapeutics Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Dianthus Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dianthus Therapeutics Beneish M-Score Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
0.00 0.00 0.00 13.39 -4.75

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.77 6.35 -0.82 -4.75 0.11

DNTH vs CAI, TNGX, MANE: Beneish M-Score Comparison

For the Biotechnology subindustry, Dianthus Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dianthus Therapeutics Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dianthus Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Dianthus Therapeutics's Beneish M-Score falls into.


DNTH
22GF Score
Dianthus Therapeutics Inc DNTH
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dianthus Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Dianthus Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 6.0064+0.528 * 1+0.404 * 0.4616+0.892 * 0.2048+0.115 * 1.1021
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 7.2197+4.679 * -0.034013-0.327 * 0.6054
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was $1.23 Mil.
Revenue was 0.463 + 0.284 + 0.396 + 0.193 = $1.34 Mil.
Gross Profit was 0.463 + 0.284 + 0.396 + 0.193 = $1.34 Mil.
Total Current Assets was $1,119.91 Mil.
Total Assets was $1,246.88 Mil.
Property, Plant and Equipment(Net PPE) was $1.57 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.37 Mil.
Selling, General, & Admin. Expense(SGA) was $39.46 Mil.
Total Current Liabilities was $38.28 Mil.
Long-Term Debt & Capital Lease Obligation was $0.97 Mil.
Net Income was -40.834 + -64.432 + -36.765 + -31.629 = $-173.66 Mil.
Non Operating Income was -0.566 + -0.158 + -0.135 + -0.105 = $-0.96 Mil.
Cash Flow from Operations was -28.856 + -46.983 + -30.555 + -23.892 = $-130.29 Mil.
Total Receivables was $1.00 Mil.
Revenue was 1.163 + 1.326 + 2.172 + 1.863 = $6.52 Mil.
Gross Profit was 1.163 + 1.326 + 2.172 + 1.863 = $6.52 Mil.
Total Current Assets was $271.00 Mil.
Total Assets was $348.58 Mil.
Property, Plant and Equipment(Net PPE) was $1.64 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.44 Mil.
Selling, General, & Admin. Expense(SGA) was $26.69 Mil.
Total Current Liabilities was $16.95 Mil.
Long-Term Debt & Capital Lease Obligation was $1.17 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1.23 / 1.336) / (1 / 6.524)
=0.920659 / 0.15328
=6.0064

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(6.524 / 6.524) / (1.336 / 1.336)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1119.911 + 1.567) / 1246.884) / (1 - (270.999 + 1.638) / 348.58)
=0.100576 / 0.217864
=0.4616

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1.336 / 6.524
=0.2048

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.438 / (0.438 + 1.638)) / (0.371 / (0.371 + 1.567))
=0.210983 / 0.191434
=1.1021

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(39.462 / 1.336) / (26.691 / 6.524)
=29.537425 / 4.091202
=7.2197

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.965 + 38.283) / 1246.884) / ((1.17 + 16.953) / 348.58)
=0.031477 / 0.051991
=0.6054

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-173.66 - -0.964 - -130.286) / 1246.884
=-0.034013

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Dianthus Therapeutics has a M-score of 0.11 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 0.11 mean?
Dianthus Therapeutics (DNTH) has a Beneish M-Score of 0.11 as of Jul. 05, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Dianthus Therapeutics and its competitors. This is 98% below median its historical median of 6.35. According to the industry distribution chart, Dianthus Therapeutics ranks #694 out of 825 companies in the Biotechnology industry, placing it in the top 84.1%.
Is Dianthus Therapeutics' Beneish M-Score too high?
Dianthus Therapeutics' current Beneish M-Score of 0.11 is 98% below median its 10-year median of 6.35. Based on the distribution chart, Dianthus Therapeutics ranks #694 out of 825 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Dianthus Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dianthus Therapeutics' Beneish M-Score compare to CAI and TNGX?
According to the Biotechnology industry distribution chart, Dianthus Therapeutics ranks #694 out of 825 companies for Beneish M-Score. This places Dianthus Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Dianthus Therapeutics and its competitors. Dianthus Therapeutics's current Beneish M-Score is 0.11, which is 98% below median its own 10-year median of 6.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dianthus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Dianthus Therapeutics (DNTH) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.91, compared to a current price of $94.34 — trading 3141.9% above its estimated fair value. The current Beneish M-Score is 0.11, which is 98% below median its 10-year median of 6.35. Dianthus Therapeutics' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Dianthus Therapeutics (DNTH), the current Beneish M-Score is 0.11 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dianthus Therapeutics (DNTH) Overvalued in 2026?

Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued. The current stock price of $94.34 is trading 3141.9% above its estimated GF Value™ of $2.91. GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.

Key valuation signals for DNTH:

  • Beneish M-Score: 0.11 (98% below median its 10-year median of 6.35)
  • GF Value™: $2.91 vs. price of $94.34 (3141.9% above fair value)
  • GF Score™: 22/100 with 7 warning signs

No single metric tells the full story. See the DNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dianthus Therapeutics Business Description

Other Exchanges 87E:Germany
Address 7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
22GF Score

Get the complete analysis for DNTH

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$94.34
Price
$2.91
GF Value